Data demonstrates the significant and sustained tumor regression achieved by the CAPTN-3 platform across two distinct tri-specific antibodies, IM1240 and IM1305, targeting different tumor antigens Transcriptomic analysis across ~11,000 TCGA samples shows NKG2A expression is strongly associated with tumor expression of 5T4 or TROP2, supporting inclusion of the NKG2A arm in CAPTN-3 designs NKG2A arm significantly contributes to IM1240 anti-cancer immune activity in PD1-resistant patient-derived explants REHOV ...

New data showcase the versatility and anti-tumor activity of the CAPTN-3 platform and its unique multi-arm design in treatment-resistant cancers     REHOVOT, Israel, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, today announced that it will present new preclinical data from its CAPTN-3 platform of conditionally activated ...

Core Insights - Purple Biotech Ltd. has initiated the development of a second tri-specific antibody, IM1305, targeting TROP2, and achieved a manufacturing milestone for its first tri-specific antibody, IM1240, which targets 5T4 [1][4] - The company reported a cash position of $10.5 million as of September 30, 2025, with an expected cash runway into the first half of 2027, supporting the development of its CAPTN-3 technology platform [1][10] Financial Performance - Research and Development Expenses for the three months ended September 30, 2025, were $0.6 million, a decrease of 56.4% from $1.3 million in the same period of 2024, primarily due to reduced costs associated with the CM24 Phase 2 study [5] - General and Administrative Expenses remained consistent at $0.8 million for the three months ended September 30, 2025, compared to the same period in 2024 [6] - The Operating Loss for the three months ended September 30, 2025, was $1.4 million, a decrease of 35.8% from $2.1 million in the same period of 2024 [6] - The Net Loss for the three months ended September 30, 2025, was $1.3 million, or $0.29 per basic and diluted ADS, compared to a net loss of $0.7 million, or $0.39 per basic and diluted ADS, in the same period of 2024 [9] Clinical and Corporate Developments - The company plans to conduct non-GLP and GLP toxicology studies, submit an Investigational New Drug application (IND), and initiate a Phase 1 study for IM1240 in 2026 [2] - IM1240 has demonstrated tumor cell death in patient-derived, treatment-resistant head and neck biopsies, advancing toward first-in-human clinical trials [4] - The CM24 Phase 2 study will utilize identified biomarkers for patient selection in the upcoming Phase 2b study, which is subject to partnering [4] Patent and Intellectual Property - Purple Biotech received an intention to grant a European patent covering NT219 combinations with immunotherapies or MEK inhibitors to overcome tumor resistance [3][5]

Core Points - Purple Biotech Ltd. has received a notification from Nasdaq regarding non-compliance with the minimum bid price requirement, as the closing bid price for its American Depositary Shares (ADSs) has been below $1.00 for 30 consecutive trading days [1] - The company has a 180-day period until April 14, 2026, to regain compliance by achieving a closing bid price of $1.00 or more for at least ten consecutive business days [2] - The notification does not affect the company's current Nasdaq listing or trading of its ADSs, which will continue under the symbol "PPBT" [3] Compliance and Remediation - If compliance is not regained by April 14, 2026, the company may be eligible for an additional 180 days to cure the deficiency, provided it meets other listing requirements [4] - The company intends to monitor its ADS closing bid price and may consider options to regain compliance, including potentially changing the ADS to ordinary shares ratio [5] Company Overview - Purple Biotech is a clinical-stage company focused on developing first-in-class therapies to combat tumor immune evasion and drug resistance, with a pipeline that includes CAPTN-3, CM24, and NT219 [6] - CAPTN-3 is a preclinical platform utilizing tri-specific antibodies to enhance immune response within the tumor microenvironment, while CM24 is a humanized monoclonal antibody targeting CEACAM1 to block tumor immune evasion [6][7] - NT219 is a novel small molecule that targets IRS1/2 and STAT3, showing anti-tumor activity in combination with cetuximab in clinical studies [7]

Kura Oncology Conference Call Summary Company Overview - **Company**: Kura Oncology (NasdaqGS: KURA) - **Focus**: Development of targeted therapies for cancer treatment, particularly through the use of Farnesyl Transferase Inhibitors (FTIs) and menin inhibitors. Key Points Industry and Product Pipeline - Kura is well-positioned to build on the success of Ziftomenib, currently under FDA review for NPM1-mutant relapsed/refractory Acute Myeloid Leukemia (AML) [3][4] - The menin inhibitor class could represent a market opportunity of $5 to $10 billion, with Kura aiming to capture a significant share [3] - The company is advancing its FTI program, specifically KO-2806 (Darlifarnib), which is designed to overcome drug resistance in various cancers [12][26] Preclinical Data and Mechanism of Action - KO-2806 has shown improved potency and reduced dosing requirements compared to its predecessor, Tipifarnib, making it suitable for combination therapies [12][13] - The FTI program targets Rheb, a protein involved in mTOR signaling, which is crucial for addressing resistance to multiple targeted therapies [8][18] - Preclinical studies indicate that KO-2806 enhances the efficacy of various therapies, including PI3K inhibitors, KRAS inhibitors, and anti-angiogenic TKIs, across multiple cancer types [26][27] Clinical Development Strategy - Kura is conducting several clinical trials, including: - A dose escalation trial for KO-2806 in RAS mutant tumors [30] - A combination trial of KO-2806 with Cabozantinib in renal cell carcinoma [31] - A trial combining Tipifarnib with Alpelisib in PIK3CA mutant head and neck squamous cell carcinoma [32] - The company anticipates presenting data at the upcoming ESMO meeting, focusing on safety, tolerability, and efficacy of these combinations [27][30] Market Opportunity - Kura estimates a patient population of over 200,000 annually in the U.S. for potential applications of FTIs in combination with other targeted therapies [34] - The company is optimistic about the commercial launch of Ziftomenib and ongoing studies, including the KOMET-001 phase three studies [35][36] Financial Position - Kura reported $630.7 million in cash and cash equivalents, with anticipated milestone payments of $375 million expected by year-end [36] Future Directions - Kura is exploring various clinical collaborations and partnerships to enhance the development of KO-2806 and its applications across different cancer types [60][61] - The company aims to demonstrate the additive efficacy of KO-2806 in combination therapies, addressing the challenge of proving its value alongside established agents [81] Additional Insights - The call highlighted the importance of demonstrating single-agent activity for future development, although Kura is currently focused on combination therapies [52] - The potential for KO-2806 to overcome resistance mechanisms associated with other combination regimens was also discussed, indicating a broad applicability of the FTI approach [81] This summary encapsulates the key points from the Kura Oncology conference call, focusing on the company's strategic direction, product pipeline, and market opportunities.

Core Insights - Kura Oncology is showcasing the potential of KO-2806 (darlifarnib) in combination with various targeted therapies to enhance anti-tumor activity and address resistance mechanisms in cancer treatment [1][2][4] Group 1: KO-2806 Development and Clinical Data - KO-2806 is a next-generation farnesyl transferase inhibitor (FTI) designed for superior potency and pharmacokinetics compared to first-generation candidates [4] - Preliminary clinical data for KO-2806 will be presented at the ESMO Congress 2025 in October [1][5] - The company is conducting ongoing Phase 1 trials for KO-2806, with a focus on its combination with standard-of-care agents [4] Group 2: Mechanisms of Action and Preclinical Findings - KO-2806 has shown robust preclinical activity by suppressing mTOR signaling, enhancing the efficacy of antiangiogenic TKIs, PI3Kα inhibitors, and KRAS inhibitors [4] - The preclinical studies indicate that KO-2806 can re-sensitize tumors in non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) models to KRAS inhibitors [4] - The findings suggest broad applicability across multiple cancer types, potentially impacting over 200,000 new patients annually in the U.S. [4] Group 3: Future Events and Presentations - Kura plans a second analyst/investor event on October 18, 2025, to review clinical data from the ESMO Congress presentations [5] - The company emphasizes the importance of innovative combination therapies to overcome resistance in cancer treatment [2][4]

Core Viewpoint - Purple Biotech Ltd. is advancing its clinical-stage therapies, particularly NT219, which targets tumor immune evasion and drug resistance, and has received an intention to grant a European Patent for its combination therapies [1][2][3] Company Overview - Purple Biotech is a clinical-stage company focused on developing first-in-class therapies to combat tumor immune evasion and drug resistance, with a pipeline that includes NT219, CAPTN-3, and CM24 [4] - The company is headquartered in Rehovot, Israel, and is publicly traded on NASDAQ and TASE under the ticker PPBT [4] Patent and Intellectual Property - The European Patent Office intends to grant a patent for NT219 combinations with leading immunotherapies, which could provide broad protection until 2036 [2] - The patent covers combinations of NT219 with various immunotherapies and chemotherapies, aimed at enhancing treatment sensitivity for resistant tumors [2] Clinical Development - A Phase 2 study for NT219 in combination with immunotherapy is underway, specifically targeting squamous cell carcinoma of the head and neck [3][5] - The study evaluates NT219 with pembrolizumab and cetuximab, building on previous Phase 1 results that showed anti-tumor activity [3][5] - Preclinical data supports the synergistic effects of NT219 with immunotherapy, indicating a shift in the tumor microenvironment from immunosuppressive to immunoreactive [3] Therapeutic Mechanism - NT219 functions as a dual inhibitor targeting IRS1/2 and STAT3, both of which are critical in drug resistance and tumor immune evasion [3][5] - The company is also developing CAPTN-3, a platform of tri-specific antibodies designed to enhance immune response within the tumor microenvironment [4]

Core Viewpoint - Purple Biotech Ltd. has successfully closed a public offering of 5,999,999 American Depositary Shares (ADSs) at a price of $1.00 per share, with additional short-term warrants potentially raising gross proceeds of approximately $12 million if fully exercised [1][3]. Group 1: Offering Details - The public offering included 5,999,999 ADSs, each representing 200 ordinary shares, and short-term warrants to purchase up to 11,999,998 ADSs [1]. - The gross proceeds from the offering were approximately $6 million before deducting fees and expenses [3]. - The short-term warrants have an exercise price of $1.00 per ADS and are exercisable immediately, expiring twenty-four months from issuance [1][3]. Group 2: Use of Proceeds - The net proceeds from the offering will be used for the development of oncology therapeutic candidates and for general working capital and corporate purposes [3]. Group 3: Company Overview - Purple Biotech is a clinical-stage company focused on developing first-in-class therapies to overcome tumor immune evasion and drug resistance [6]. - The company's oncology pipeline includes CAPTN-3, CM24, and NT219, with CAPTN-3 being a preclinical platform of conditionally activated tri-specific antibodies [6]. - CM24 is a humanized monoclonal antibody targeting CEACAM1, and NT219 is a dual inhibitor targeting IRS1/2 and STAT3, with ongoing clinical studies demonstrating anti-tumor activity [6].

Company Overview - Purple Biotech Ltd. is a clinical-stage company focused on developing first-in-class therapies to overcome tumor immune evasion and drug resistance [6] - The company's oncology pipeline includes CAPTN-3, CM24, and NT219, with innovative mechanisms targeting various cancer indications [6][7] Public Offering Details - Purple Biotech announced a public offering of 5,999,999 American Depositary Shares (ADSs) at a price of $1.00 per share, with short-term warrants to purchase up to 11,999,998 ADSs [1][3] - The gross proceeds from the offering are expected to be approximately $6 million, with potential additional proceeds of about $12 million from the exercise of short-term warrants [3] Use of Proceeds - The net proceeds from the offering will be utilized for the development of oncology therapeutic candidates and for general working capital and corporate purposes [3] Regulatory Information - The offering is conducted under a registration statement on Form F-1, which was declared effective by the SEC on September 4, 2025 [4]

Company Overview - Purple Biotech Ltd. is a clinical-stage company focused on developing first-in-class therapies to overcome tumor immune evasion and drug resistance [3] - The company's oncology pipeline includes CAPTN-3, CM24, and NT219, which are designed to enhance immune response against tumors [3] Pipeline Details - CAPTN-3 is a preclinical platform of conditionally activated tri-specific antibodies that engage T cells and NK cells to induce a localized immune response within the tumor microenvironment [3] - CM24 is a humanized monoclonal antibody that blocks CEACAM1, a target that supports tumor immune evasion and survival [3] - NT219 is a dual inhibitor targeting IRS1/2 and STAT3, showing anti-tumor activity in combination with cetuximab for recurrent and/or metastatic squamous cell carcinoma of the head and neck [3] Recent Events - The CEO of Purple Biotech, Gil Efron, will participate in a fireside chat and 1x1 investor meetings at the H.C. Wainwright 27 Annual Global Investment Conference scheduled for September 8-10, 2025 [1][2]